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The receptor  for  the  inhibitory  neurotransmitter  gly- 
cine is a member  of the  ligand-gated ion channel  recep- 
tor  superfamily.  Point  mutations in the gene encoding 
the a1 subunit  of  the  glycine  receptor-channel  complex 
(GlyR)  have  recently  been identified in pedigrees  with 
the  autosomal  dominant  neurological  disorder,  startle 
disease (hyperekplexia).  These  mutations  result in the 
substitution  of  leucine  or  glutamine  for  arginine 271. 
This charged residue is located near the ion channel 
region and is predicted to affect chloride permeation 
through  the GlyR. We found little evidence  for this role 
from the aniodcation selectivity and  lack  of  pro- 
nounced rectification of currents  flowing  through re- 
combinant human al subunit GlyRs containing the 
startle disease mutations. We reveal,  however,  that  the 
startle disease mutations  profoundly  disrupt GlyR func- 
tion by causing 230-410-fold  decreases in the sensitivity 
of  receptor  currents activated by  the  agonist  glycine. 
Additionally,  we  report  corresponding 56- and  120-fold 
reductions in the  apparent  binding  affinity ( IC i )  of gly- 
cine to  the  mutant GlyRs,  but  no  change in the  binding 
affinity  of  the  competitive  antagonist,  strychnine. Thus, 
startle disease reduces  the  efficacy  of  glycinergic  inhibi- 
tory  neurotransmission  by  producing GlyRs with  dimin- 
ished agonist responsiveness. Our results show that 
startle disease mutations  define  a  novel  receptor  activa- 
tion site. 
The glycine receptor (G1yR)l is a  member of the  ligand-gated 
ion channel  superfamily (1-3) of neurotransmitter receptors 
responsible  for fast  synaptic  transmission  in  the nervous  sys- 
tem. Members of this superfamily, which includes the receptors 
for  y-aminobutyric  acid (GABA,R), acetylcholine (nAChR), and 
5-hydroxytryptamine, share considerable  sequence and  struc- 
tural homology. Receptors are comprised of five subunits,  ar- 
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ranged  in  the postsynaptic membrane of neurons so as to  form 
a central, ion channel, which in  the case of the GlyR is selective 
to C1-. Each  subunit  in  turn  contains a large  N-terminal  extra- 
cellular region and four membrane-spanning domains (Ml- 
M4), of which the second (M2) lines the ion channel (1-3). 
Binding sites for glycine and  other GlyR agonists,  and for the 
competitive antagonist, the plant alkaloid strychnine, have 
been previously  shown to be localized in  the  N-terminal  extra- 
cellular region of a subunits (4-8). 
The GlyR in vivo mediates  inhibitory  neurotransmission  in 
the  spinal cord and  brain. Reduced glycinergic inhibition 
caused by subconvulsive strychnine poisoning results  in  mus- 
cular  hypertonia,  heightened reflex excitability, and  an exag- 
gerated response to  sensory stimuli (9). These symptoms are 
similar  to  those of the  autosomal  dominant neurological disor- 
der, startle  disease, also  known as hyperekplexia  or Kok‘s dis- 
ease (10-13). This disorder is characterized by a marked mus- 
cular  hypertonia  in infancy and  an exaggerated startle 
response to unexpected  sensory stimuli  that  persists  in  adult- 
hood (10-13). The startle disease gene has been mapped to 
human chromosome 5q32 (13, 14), a region that contains  the 
genes for a number of neurotransmitter receptors including 
that for the a1 subunit of the GlyR (15). More recently, point 
mutations  in  the gene encoding the a1 subunit of the GlyR have 
been  identified in  startle  disease pedigrees (16). Reduced gly- 
cinergic inhibition  arising from the  impaired function of mu- 
tated GlyRs may  thus  underlie  the symptoms of startle disease. 
Two point mutations involving the  same  base  pair  in  the gen
encoding the a1 subunit of the GlyR have been  identified in 
four startle  disease pedigrees (16). These mutations  result  in 
the  substitution of an uncharged  amino acid (leucine or  gluta- 
mine) for a positively charged  arginine  residue a t  position 271 
(Arg-271). This  residue is located at the  extracellular  margin of 
the  channel-lining M2 region, suggesting that its mutation  may 
impair ion permeation  through  the GlyR. We investigated  the 
effects of the  startle  disease  mutations on GlyR function by 
replacing Arg-271 with either leucine (R271L) or glutamine 
(R271Q) in GlyR a1 subunit cDNA using site-directed mu- 
tagenesis.  Mutated cDNA or unmodified (WT) cDNA was  then 
transfected  into  mammalian 293 cells resulting  in  the  transient 
expression of homomeric human a1 subunit GlyRs (17, 181, 
which were subsequently analyzed using patch-clamp tech- 
niques  and [3H]strychnine binding  assays. We have found that 
startle  disease  mutations caused no major alterations  to ion 
permeation  through  the GlyR, but  rather,  dramatically reduced 
the receptor’s agonist sensitivity. This  latter finding, in addi- 
tion  to  explaining  the  startle  disease phenotype,  identifies an 
unexpected structural  determinant of GlyR function. 
EXPERIMENTAL PROCEDURES 
Expression of Mutated GlyR a1 Subunit cDNAs-Mutations in the 
human GlyR a1 subunit cDNA (18) were constructed by using the 
oligonucleotide-directed polymerase chain reaction  mutagenesis 
method (19) and were confirmed  by DNA sequencing.  The single-letter 
code for amino acids is used to describe mutations. The letter preceding 
the position number refers to  the amino acid in the wild type (WT) GlyR 
and the letter after the number refers to the amino acid replacing the 
WT amino acid.  For example, R271L refers to the mutation of arginine 
at position 271 to leucine. GlyR a1 subunit cDNA was transfected,  using 
the 3% CO, method (20) into  exponentially  growing 293 cells (21) as 
previously described (5). Patch-clamp  studies and [3Hlstrychnine bind- 
ing assays were conducted 48 h after transfection. 
Patch-Clamp Studies--Transfected cells were patch-clamped in the 
whole cell mode (22) while  continually  superfused  with a bath solution 
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TABLE I
Mean EC,, Hill coefficient (h),  and I,, values for glycine-activated 
currents  in 293 cells  expressing  WT  and  mutant  GlyRs 
The values in  parentheses  are  the -fold changes  relative to the values 
for the WT GlyRs. Data  represent  mean values  with S.E. from 5-6 cells. 
GlyR ECsa h L, 
mM nA 
WT 0.029 ? 0.004 1.6 * 0.2 5.0 ? 2.1 
(1) (1) 
R271L 
(1) 
6.7 ? 1.5 1.3 2 0.1 
(230) 
5.7 ? 2.8 
(0.8) 
R271Q 
(1.1) 
12 ? 0.6 
(410) 
1.5 * 0.1 
(0.9) 
1.8 ? 0.6 
(0.4) 
containing  (in mM) 140 NaCI, 10 glucose, 5 KCl, 2 CaCI,, 2 MgCl,, 10 
HEPES, pH 7.4. Glycine dissolved in  this solution was rapidly  applied 
to the chamber using a microperfusion tube system. Voltages were 
corrected for junction  potentials  using the JPCalc program (23). The 
pipette solution contained (in mM) 145 CsCI, 2 CaCl,, 2 MgCl,, 10 
HEPES,  10 EGTA, pH 7.4. In experiments measuring  reversal poten- 
tials CsCl was replaced by  KCl. The EC,, value and Hill coefficient ( h )  
for glycine-activated currents in individual cells were calculated by 
fitting  data  using a non-linear least  squares algorithm to  the Hill equa- 
tion: I/Imm = [Glh/(EC,,h + [GIh),  where I is  the magnitude of the peak 
current elicited by a concentration [GI  of glycine and Ima. is  the magni- 
tude of the maximum peak current elicited by saturating concentrations 
of glycine. 
PHlStrychnine Binding Assays--Transfected cells were incubated 
with  [3Hlstrychnine (1-50 n ~ ;  24.5 Ci/mM, DuPont  NEN) with  and with- 
out 10 PM cold strychnine to determine nonspecific binding. After incu- 
bation  to  equilibrium at 4 "C for 60 min, cells were collected by rapid 
filtration onto Whatman GFiB filter  paper and  the  amount of radioac- 
tive strychnine  remaining bound determined. The Kd and B,, for the 
[3Hlstrychnine saturation  isotherms  and IC,, and Ki for glycine dis- 
placement of bound [3Hlstrychnine were estimated using the InPlot 
program (Graph  Pad SoRware, San Diego, CAI. 
RESULTS AND DISCUSSION 
Glycine-activated currents were examined in WT and mu- 
tated GlyRs using  the whole cell recording mode of the patch- 
clamp  technique. For WT GlyRs, glycine application at  a hold- 
ing potential of -55 mV produced inward  currents  that showed 
a half-maximal  response (EC,,) at 0.029 mM glycine (Table I, 
Fig. 1). Much higher glycine concentrations were required  to 
elicit currents  in R271L and R271Q GlyRs (EC,, = 6.7 and 12 
m, respectively) (Table I, Fig. l), revealing that  these  muta- 
tions  caused a 230- and 410-fold reduction in glycine-activated 
current sensitivity, respectively. The activation and desensiti- 
zation  kinetics of macroscopic currents  in R271L and R271Q 
GlyRs were similar to those of WT GlyRs (Fig. lA), as were the 
Hill coefficients for activation of glycine-activated currents 
(Table I). Hence, the  startle disease mutations produced a dra- 
matic decrease in glycine sensitivity without appearing to 
affect either current kinetics or the cooperativity of glycine 
binding. 
The binding  properties of the competitive antagonist 
[3H]strychnine, with  the  mutant GlyRs, were also  examined. 
The R271L and R271Q GlyRs showed affinities and receptor 
numberskell  similar  to those for WT GlyRs (Table 11, Fig. 21, 
indicating that  these  mutations did not affect either  the e%- 
ciency of expression of GlyRs or their affinity for strychnine. 
The ability of glycine to  displace bound [3Hlstrychnine was, 
however, greatly reduced. The glycine inhibition constant for 
R271L and R271Q GlyRs (K, = 5.6 and 12 m ~ ,  respectively) 
(Table 11) was 56-120-fold higher  than  that of WT GlyRs (K, = 
0.10 m ~ )  (Table 11). Thus,  the reduced sensitivity of glycine- 
activated currents  in  mutant GlyRs is accompanied by a re- 
duced afinity of glycine binding. That  the  strychnine sensitiv- 
ity of the  mutant receptors remains unchanged is significant, 
since  binding sites for glycine and  strychnine  are  intimately 
A 
0.005 0.01 0.02 0.05 0.1 
wT"-- 
B 
0.001 0.01 0.1 1 10 100 
[Glycine] ( m M )  
cells  expressing R.271L and R.27lQ GlyRs. A, whole cell currents 
FIG. 1. Reduced sensitivity of glycine-activated  currents  in 293 
activated by glycine in 293 cells expressing WT, R271L, and R271Q 
trace. Traces are 10 s in  duration. Scale  bar, 0.5 nA (WT and R271Q 
GlyRs. Concentrations of glycine applied  (in mM) are  listed above each 
GlyRs) or 1 nA (R271L GIyR). B,  dose-response curves of peak glycine- 
activated currents.  Data  represent  mean values ? S.E. from 5-6 cells. 
TABLE I1 
K, values for glycine  displacement of bound [3Hlstrychnine in 293 cells 
Mean B,, and Kd values for PHlstrychnine  binding  isotherms  and 
expressing WT  and  mutant  GlyRs 
The  values  in  parentheses  are  the -fold changes  relative  to the values 
for the WT GlyR. Mean  values  with  S.E. from 3-5 independent deter- 
minations are shown. 
GlyR Bmaa Strychnine Kd Glycine K, 
x I @  siteslcell nM mM 
WT 1.3 ? 0.2 8.1 ? 0.3 0.10 0.02 
R271L 3.9 ? 0.6 14 ? 2.2 5.6 f 0.8 
(1) (1) (1) 
(1.7) 
associated (4-8). The reductions in glycine sensitivity but not 
strychnine sensitivity  caused by these  mutations therefore  can- 
not be due  to a general  alteration of the  structure of the ligand 
binding region of the GlyR. Other  residues exhibiting a similar 
specificity of action have previously been  identified in  the GlyR 
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(4-8) and  in  the  related GAE%A,R y-aminobutyric acid type A 
receptor  (24, 25)  and nAChR (reviewed in Ref. 26), but only in 
the N-terminal extracellular regions of these receptors. Our 
finding  that Arg-271, located at the border of the channel-lining 
M2 domain of the GlyR, is a highly specific determinant of 
agonist  activation  raises  the possibility that  the  ligand  binding 
and ion conducting  portions of the GlyR are  far more intricately 
linked  than has been  previously thought. 
The possibility that the  channel  permeation  properties of the 
GlyR were also  altered by mutation of Arg-271 was also  inves- 
tigated.  The  current-voltage  relations of peak glycine-activated 
currents in the  mutant GlyRs were indistinguishable from that 
of WT GlyRs (Fig.  3). In solutions containing equimolar 153 mM 
C1-, application of saturating  concentrations of glycine at vari- 
ous membrane potentials resulted in currents that reversed 
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R271L and R271Q GlyRs. Glycine displacement curves of bound 
FIG. 2. Reduced glycine binding affinity of 293 cells expressing 
[3H]strychnine from 293 cells expressing WT and  mutant GlyRs are 
illustrated.  Data  represent  the  mean  values * S.E. of triplicate  meas- 
urements from a  representative  experiment. 
FIG. 3. Unaltered current-voltage 
characteristics of 293 cells express- 
ing R271L and R271Q  GlyRs. A, whole 
cell currents  activated by 0.1 mM glycine 
(WT GIyR) or 50 mM glycine (R271L and 
R271Q GlyRs) at holding  potentials of -55 
mV (bottom  truces) to +45 mV (top truces) 
in  solutions  containing  equimolar  153 mM
C1- are  similar  in  shape  and  reverse close 
to 0 mV, the C1- equilibrium potential. 
Currents  have  been  corrected  for  leakage 
Traces are 5 s in  duration. Scale  bur, 4 nA 
and  voltages for junction  potentials. 
( W T  and R271L GlyRs) or 1 nA (R271Q 
GlyR). B, peak current-voltage relations 
in  solutions  containing  equimolar 153 mM 
C1-. C, for each glycine receptor, subse- 
quent 50% dilution of the  bath solution 
with  mannitol  resulted  in  a  shift of the 
reversal potential to near +19 mV, the 
new C1- equilibrium  potential.  Data  rep- 
resent  mean  currents  standardized  to  cur- 
rent  values at -55 mV with S.E. from 5 
cells ( B )  or 3 cells (C). 
close to  the C1- equilibrium potential of 0 mV. Replacement of 
the  bath with a 75 mM C1- solution shifted  the  reversal poten- 
tial of currents close to  the new C1- equilibrium potential of +19 
mV (Fig. 3C), confirming that these currents remained C1- 
selective and  that  mutation of Arg-271 did not significantly 
alter  the  relative cation-anion selectivity. Hence, Arg-271 does 
not appear  to play  a  major role in  determining  the macroscopic 
conductance properties of the GlyR. This  was  surprising, since 
this residue  has been  predicted to affect ion permeation 
through  the receptor (1,27,28). Closely corresponding residues 
in  the M2 domain of the nAChR form an  outer anionic ring of 
charge, which influences divalent cation effects on channel con- 
ductance (27). Additionally, replacement of arginine  residues a t  
positions 252 and  271  with  glutamic acid residues confers cat- 
ion selectivity to GlyR M2 peptides incorporated into lipid bi- 
layers (28). It has been reported recently that the arginine 
residue a t  position 252, located at the cytoplasmic margin of 
the M2 region of the GlyR, is critical for receptor  assembly  (29). 
Mutation of this  residue  to  either Glu or Gln prevented the 
expression of GlyRs on the cell surface. It  appears,  then,  that 
both Arg-252 and Arg-271  influence GlyR function in  manners 
that  extend beyond that of determining ion  permeation. 
Our identification of a profound decrease in agonist  sensitiv- 
ity  in  the  mutant GlyRs provides an explanation of the  startle 
disease phenotype,  since  decreased glycinergic tone in  spinal 
cord interneurons effectively reduces the  recurrent  and recip- 
rocal inhibitory feedback that  modulates  firing of motoneurons 
in reflex arcs. Reduced glycinergic inhibition also underpins 
the phenotype of the murine autosomal recessive mutation, 
spastic, a form of inherited myoclonus (30). In spastic, this 
reduction is  due  to  the  underexpression of GlyRs rather  than 
the  impairment of their function (30, 31). It is possible that 
reduced GlyR expression in vivo may also accompany startle 
disease but this appears unlikely. Our  estimates of the  number 
of GlyRs at  the cell surface from the predicted numbers of 
strychnine  binding  sites (Bma values  in Table 11) indicate that 
the efficiency of expression of mutant GlyRs was comparable to 
that of WT GlyRs. Additionally, GlyRs mutated  at Arg-271 to 
A 
WT R271 L 
B 
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n R 2 7 1 C  
Ire1 
i 
f“---- 
R27 1 Q 
C 
60 
+ 
60 
L I 
18742 Startle  Disease  Mutations Reduce GlyR  Agonist  Sensitivity 
either Glu or Gln assemble at  the cell surface in  similar  num- 
bers to WT GlyRs (29). These  mutated receptors  were  reported 
to be non-functional, although our data indicate that  at  least 
the R271Q GlyRs are capable of forming glycine-gated 
channels. 
Startle disease is  rarely  lethal (10-131, suggesting that  the 
magnitude of the glycine insensitivity we report in homomeric 
a1 subunit GlyRs may  be less  extreme  in  spinal cord GlyRs due 
to  a dominant negative effect (32). Startle disease heterozy- 
gotes, in which both a normal and disease gene are  present, will 
on average,  contain only 1.5 mutated a1 subunits  in each pen- 
tameric GlyR, spinal cord GlyRs being comprised of a and p 
subunits  in a 3:2 stoichiometry (33). Whilst the effects of startle 
disease mutations are clearly observed using a1 homomeric 
GlyRs, examination of multi-subunit recombinant GlyRs 
should further define the  startle disease phenotype. A point 
mutation  in  the  N-terminal  extracellular portion of the  gene 
encoding the a1 subunit of the GlyR has also been identified in 
the  murine  mutation spasmodic (34). The spasmodic  phenotype 
resembles both that of startle disease and spastic. When ex- 
pressed in homomeric a1 subunit GlyRs, however, this  muta- 
tion resulted  in only a 6-fold reduction in agonist  sensitivity 
(34). The spasmodic mutation, like spastic, is an  autosomal 
recessive mutation. Therefore,  all a1 subunits  present  in spas- 
modic spinal cord GlyRs will  be of the disease  type. Thus,  the 
reduced agonist sensitivity of spasmodic and  startle disease 
GlyRs may be  more comparable in vivo. In summary, the  startle 
disease mutations identified a t   kg-271 have revealed an  un- 
expected structural  determinant of GlyR function. Analysis of 
other  startle disease mutations may provide further  important 
insights  into  the mechanisms of action of the ligand-gated ion 
channel receptor superfamily. 
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